quantifi impact enbrel patent
maintain market perform rate share
increas price target follow
friday posit district court decis enbrel patent
valid enbrel patent affirm adjust sale
estim reflect stabl trend lack biosimilar eros
beyond estim npv impact roughli
increas ep compound-annual-growth-rate
previous share trade high end larg cap
biotech peer believ stock fully-valu rel growth
even upward revis enbrel estim
announc late friday district
court district new jersey rule two patent describ
enbrel method make valid preliminari
injunct set june regard sandoz biosimilar enbrel
remain place sandoz acknowledg product infring
claim patent trial
proceed valid claim court found
sandoz met primari burden proof claim
invalid
posit court decis valid patent
enbrel exclus support key patent extend april
includ method treat psoriasi method august
fusion protein
pharmaceut composit composit matter novemb
dna encod fusion protein method make
fusion protein method composit april
formul method
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani data secur llc estim reuter
price target
arriv price target appli multipl ep estim risk includ
greater expect eros base biolog busi competit kyproli gener
velcad emerg myeloma treatment failur gain approv proprietari biosimilar
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
